Meeting Banner
Abstract #3924

MRS measurement of succinate in vivo as a biomarker in succinate dehydrogenase deficient tumours

Mary A McLean1, Ruth T Casey2,3, Benjamin G Challis3, Rogier ten Hoopen4, Thomas Roberts5, Graeme R Clark2, Deborah Pittfield3, Helen L Simpson6, Venkata R Bulusu7, Kieran Allinson8, Lisa Happerfield9, Soo-Mi Park2, Alison Marker8, Olivier Giger4, Basetti Madhu1, Eamonn R Maher2, and Ferdia A Gallagher10

1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom, 2Medical Genetics, University of Cambridge, Cambridge, United Kingdom, 3Endocrinology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom, 4Pathology, University of Cambridge, Cambridge, United Kingdom, 5Haematology Oncology, University of Cambridge, Cambridge, United Kingdom, 6Diabetes and Endocrinology, UCLH NHS Foundation Trust, London, United Kingdom, 7Medical Oncology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom, 8Histopathology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom, 9Immunohistochemistry, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom, 10Radiology, University of Cambridge, Cambridge, United Kingdom

We performed respiratory-gated single-voxel 1H-MRS (TE = 144ms; voxel size 2.2-100ml; 96-512 averages) at 3T in tumours with suspected mutations in the mitochondrial enzyme succinate dehydrogenase (SDH) in 15 patients, analysed using LCModel. A germline mutation or epimutation in one of the SDH genes was identified in 11/15 subjects, with concordant MRS findings in 9 subjects, data rejection as technical failure in 4, and equivocal results in 2. Referencing succinate peaks to choline was an important quality control for discrimination of true from false negatives. MRS may provide a useful biomarker of SDH activity in this patient group.

This abstract and the presentation materials are available to members only; a login is required.

Join Here